These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 32690869)

  • 1. BRD4 regulates key transcription factors that drive epithelial-mesenchymal transition in castration-resistant prostate cancer.
    Shafran JS; Jafari N; Casey AN; Győrffy B; Denis GV
    Prostate Cancer Prostatic Dis; 2021 Mar; 24(1):268-277. PubMed ID: 32690869
    [TBL] [Abstract][Full Text] [Related]  

  • 2. BRD4 Regulates Metastatic Potential of Castration-Resistant Prostate Cancer through AHNAK.
    Shafran JS; Andrieu GP; Györffy B; Denis GV
    Mol Cancer Res; 2019 Aug; 17(8):1627-1638. PubMed ID: 31110158
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting the BRD4-HOXB13 Coregulated Transcriptional Networks with Bromodomain-Kinase Inhibitors to Suppress Metastatic Castration-Resistant Prostate Cancer.
    Nerlakanti N; Yao J; Nguyen DT; Patel AK; Eroshkin AM; Lawrence HR; Ayaz M; Kuenzi BM; Agarwal N; Chen Y; Gunawan S; Karim RM; Berndt N; Puskas J; Magliocco AM; Coppola D; Dhillon J; Zhang J; Shymalagovindarajan S; Rix U; Kim Y; Perera R; Lawrence NJ; Schonbrunn E; Mahajan K
    Mol Cancer Ther; 2018 Dec; 17(12):2796-2810. PubMed ID: 30242092
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting Bromodomain and Extra-Terminal (BET) Family Proteins in Castration-Resistant Prostate Cancer (CRPC).
    Welti J; Sharp A; Yuan W; Dolling D; Nava Rodrigues D; Figueiredo I; Gil V; Neeb A; Clarke M; Seed G; Crespo M; Sumanasuriya S; Ning J; Knight E; Francis JC; Hughes A; Halsey WS; Paschalis A; Mani RS; Raj GV; Plymate SR; Carreira S; Boysen G; Chinnaiyan AM; Swain A; de Bono JS;
    Clin Cancer Res; 2018 Jul; 24(13):3149-3162. PubMed ID: 29555663
    [No Abstract]   [Full Text] [Related]  

  • 5. BET bromodomain-mediated interaction between ERG and BRD4 promotes prostate cancer cell invasion.
    Blee AM; Liu S; Wang L; Huang H
    Oncotarget; 2016 Jun; 7(25):38319-38332. PubMed ID: 27223260
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Androgens induce a distinct response of epithelial-mesenchymal transition factors in human prostate cancer cells.
    Colditz J; Rupf B; Maiwald C; Baniahmad A
    Mol Cell Biochem; 2016 Oct; 421(1-2):139-47. PubMed ID: 27562825
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HDAC inhibition impedes epithelial-mesenchymal plasticity and suppresses metastatic, castration-resistant prostate cancer.
    Ruscetti M; Dadashian EL; Guo W; Quach B; Mulholland DJ; Park JW; Tran LM; Kobayashi N; Bianchi-Frias D; Xing Y; Nelson PS; Wu H
    Oncogene; 2016 Jul; 35(29):3781-95. PubMed ID: 26640144
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Systematic analysis of the BET family in adrenocortical carcinoma: The expression, prognosis, gene regulation network, and regulation targets.
    Situ Y; Liang Q; Zeng Z; Chen J; Shao Z; Xu Q; Lu X; Cui Y; Zhang J; Lu L; Deng L
    Front Endocrinol (Lausanne); 2023; 14():1089531. PubMed ID: 36793283
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Functional and Mechanistic Interrogation of BET Bromodomain Degraders for the Treatment of Metastatic Castration-resistant Prostate Cancer.
    Kregel S; Malik R; Asangani IA; Wilder-Romans K; Rajendiran T; Xiao L; Vo JN; Soni T; Cieslik M; Fernadez-Salas E; Zhou B; Cao X; Speers C; Wang S; Chinnaiyan AM
    Clin Cancer Res; 2019 Jul; 25(13):4038-4048. PubMed ID: 30918020
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of LSD1 by Pargyline inhibited process of EMT and delayed progression of prostate cancer in vivo.
    Wang M; Liu X; Guo J; Weng X; Jiang G; Wang Z; He L
    Biochem Biophys Res Commun; 2015 Nov; 467(2):310-5. PubMed ID: 26435505
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epithelial-Mesenchymal Transition Signaling and Prostate Cancer Stem Cells: Emerging Biomarkers and Opportunities for Precision Therapeutics.
    Chaves LP; Melo CM; Saggioro FP; Reis RBD; Squire JA
    Genes (Basel); 2021 Nov; 12(12):. PubMed ID: 34946849
    [TBL] [Abstract][Full Text] [Related]  

  • 12. DUB3 Promotes BET Inhibitor Resistance and Cancer Progression by Deubiquitinating BRD4.
    Jin X; Yan Y; Wang D; Ding D; Ma T; Ye Z; Jimenez R; Wang L; Wu H; Huang H
    Mol Cell; 2018 Aug; 71(4):592-605.e4. PubMed ID: 30057199
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exploitation of Castration-Resistant Prostate Cancer Transcription Factor Dependencies by the Novel BET Inhibitor ABBV-075.
    Faivre EJ; Wilcox D; Lin X; Hessler P; Torrent M; He W; Uziel T; Albert DH; McDaniel K; Kati W; Shen Y
    Mol Cancer Res; 2017 Jan; 15(1):35-44. PubMed ID: 27707886
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Loss of
    Cmero M; Kurganovs NJ; Stuchbery R; McCoy P; Grima C; Ngyuen A; Chow K; Mangiola S; Macintyre G; Howard N; Kerger M; Dundee P; Ruljancich P; Clarke D; Grummet J; Peters JS; Costello AJ; Norden S; Ryan A; Parente P; Hovens CM; Corcoran NM
    JCO Precis Oncol; 2021 Jun; 5():. PubMed ID: 34322653
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer.
    Asangani IA; Dommeti VL; Wang X; Malik R; Cieslik M; Yang R; Escara-Wilke J; Wilder-Romans K; Dhanireddy S; Engelke C; Iyer MK; Jing X; Wu YM; Cao X; Qin ZS; Wang S; Feng FY; Chinnaiyan AM
    Nature; 2014 Jun; 510(7504):278-82. PubMed ID: 24759320
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Do the expressions of epithelial-mesenchymal transition proteins, periostin, integrin-α4 and fibronectin correlate with clinico-pathological features and prognosis of metastatic castration-resistant prostate cancer?
    Konac E; Kiliccioglu I; Sogutdelen E; Dikmen AU; Albayrak G; Bilen CY
    Exp Biol Med (Maywood); 2017 Dec; 242(18):1795-1801. PubMed ID: 28836852
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plk1 Inhibition Enhances the Efficacy of BET Epigenetic Reader Blockade in Castration-Resistant Prostate Cancer.
    Mao F; Li J; Luo Q; Wang R; Kong Y; Carlock C; Liu Z; Elzey BD; Liu X
    Mol Cancer Ther; 2018 Jul; 17(7):1554-1565. PubMed ID: 29716963
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MicroRNA-200a suppresses prostate cancer progression through BRD4/AR signaling pathway.
    Guan H; You Z; Wang C; Fang F; Peng R; Mao L; Xu B; Chen M
    Cancer Med; 2019 Apr; 8(4):1474-1485. PubMed ID: 30784214
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel forms of prostate cancer chemoresistance to successful androgen deprivation therapy demand new approaches: Rationale for targeting BET proteins.
    Mori JO; Shafran JS; Stojanova M; Katz MH; Gignac GA; Wisco JJ; Heaphy CM; Denis GV
    Prostate; 2022 Jun; 82(10):1005-1015. PubMed ID: 35403746
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Co-targeting BET, CBP, and p300 inhibits neuroendocrine signalling in androgen receptor-null prostate cancer.
    Choo N; Keerthikumar S; Ramm S; Ashikari D; Teng L; Niranjan B; Hedwards S; Porter LH; Goode DL; Simpson KJ; Taylor RA; Risbridger GP; Lawrence MG
    J Pathol; 2024 Jun; 263(2):242-256. PubMed ID: 38578195
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.